Patents
Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
Patent Number: 7,192,769The current invention teaches methods of generating 3-dimensional culture conditions for the expansion of lymphocytes out of hematopoietic stem cells. The invention specifically covers the production of T cells through the culture of a hematopoietic stem cell together with a lymphoid stromal element in the presence of an antigen presenting cell. Lymphoid stromal elements may be allogeneic...
Inventors: Pykett; Mark J. (Boxford, MA), Rosenzweig; Michael (Boston, MA), Scadden; David T. (Weston, MA), Poznansky; Mark C. (Charlestown, MA)
Assignee: Cytomatrix, LLC (Chelmsford, MA)
Date of First Priority Issue: Thursday November 12th, 1998
Treatment and diagnosis of alzheimer's disease
Patent Number: 7,189,703This patent covers the treatment of Alzheimer's disease by antibiotic therapy. Covered include various macrolides such as azithromycin, clarithromycin, dirithromycin, erythromycin and troleandomycin. The rationale is that Alzheimer's disease patients are infected with C. pneumoniae, which is demonstrated in the examples section. The inventor of the patent also published that C...
Inventors: Balin; Brian J. (Paoli, PA), Abrams; J. Todd (Merion, PA), Hudson; Alan P. (Novi, MI), Whittum-Hudson; Judith A. (Novi, MI)
Assignee: Intracell, LLC (Merion, PA)
Date of First Priority Issue: Friday January 9th, 1998
Methods for promoting wound healing
Patent Number: 7,189,746The stimulation of healing processes after injury involves a neurological component. The inventors of the patent clearly demonstrate through several prior art examples that wound repair requires innervation of the peripheral tissue, and that damage to the surrounding nerves results in inhibition of wound repair. For example, the inventor describes a paper (Huang et al. Influence of cutaneous...
Inventors: Weinstein; David E. (Dobbs Ferry, NY)
Assignee: GliaMed, Inc. (New York, NY)
Date of First Priority Issue: Friday November 8th, 2002
Neural stem cells and use thereof for brain tumor therapy
Patent Number: 7,186,409The current patent teaches that exogenous neural stem cells can migrate to the area of various brain cancers. The patent covers the use of neural stem cells as a trojan horse to carry enzymes that activate prodrugs into active drugs in proximity to a tumor in order to induce cancer cell death.
Inventors: Snyder; Evan Y. (Jamaica Plain, MA), Breakefield; Xandra O. (Newton Center, MA), Aboody; Karen S. (Needham, MA), Herrlinger; Ulrich (Tuebingen, DE), Lynch; William P. (Ravenna, OH)
Assignee: The Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Friday August 14th, 1998
2 Comments
2 Comments
Methods of producing neurons
Patent Number: 7,186,557The current patent teaches methods of inducing differentiation of various adult stem cells into neuronal-like cells through culture on a blood clot alone or in the presence of various other cells and/or growth factors. It is known that various components released during the blood clotting process are mitogenic to stem cells, compoenents such as PDGF and FGF-2. This patent is useful for the...
Inventors: Marko; Olga (Houston, TX)
Assignee: Isolagen Technologies, Inc. (Houston, TX)
Date of First Priority Issue: Friday June 13th, 2003
Keratinocytes obtained from embryonic stem cells of mammals
Patent Number: 7,186,558The current patent is useful for parties interested in generation of keratinocytes from embryonic stem cells. The patent covers the induction of differentiation of embryonic stem cells into keratinocytes through exposure of embryonic stem cells to various extracellular matrices obtained from a mammal. Specific ECM proteins include laminin-5, type IV collage, type I collagen or fibronectins.
Inventors: Aberdam; Daniel (Nice, FR), Coraux; Christelle (Nice, FR)
Assignee: INSERM (Paris, FR)
Date of First Priority Issue: Thursday May 31st, 2001
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
Patent Number: 7,186,688VEGF (vascular endothelial growth factor) is a potent endothelial cell mitogen that has previously been used in clinical trials for therapeutic angiogenesis. The current patent covers the use of specific fragments of VEGF for the stimulation of angiogenesis and the treatment of various conditions. Specific conditions for treatment include limb ischemia, cardiovascular disease and acceleration of...
Inventors: Hu; Jing-Shan (Sunnyvale, CA), Rosen; Craig A. (Laytonsville, MD), Cao; Liang (Hong Kong, CN)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Tuesday March 8th, 1994
In vitro propagation of embryonic stem cells
Patent Number: 7,186,883Murine embryonic stem cell lines have revolutionized molecular biology by allowing the generation of transgenic and knockout mice. This technology allows for in vivo understanding of specific genes through either inducing over expression or complete silencing in a live animal. This patent covers methods of generating murine embryonic stem cells.
Inventors: Williams; Robert Lindsay (Warrandyte, AU), Gough; Nicholas Martin (North Balwyn, AU), Hilton; Douglas James (Warrandyte, AU)
Assignee: Zenyth Operations Pty Ltd. (Victoria, AU)
Date of First Priority Issue: Thursday May 31st, 1990
NK-2 homeobox transcription factor
Patent Number: 7,183,397The NK-2 homeobox transcription factor family are responsible for tissue specification and are found in a variety of stem cells. The ability to modulate such transcription factors has numerous applications in the area of stem cells since such modulation could be used to guide differentiation into specific tissues. The current patent claims the composition of matter for one such family member...
Inventors: Wilm; Claudia (Darmstadt, DE)
Assignee: Merck Patent GmbH (Darmstadt, DE)
Date of First Priority Issue: Wednesday December 1st, 1999
Vaccine immunotherapy for immune suppressed patients
Patent Number: 7,182,942Cancer vaccines have had a checkered past. This is primarily because numerous experimental approaches that demonstrated animal efficacy could not be translated into humans. Since numerous animal models are in-bred and involve carcinogenesis that is unnaturally “fast” (e.g. either a cell line is injected or huge amounts of carcinogens are administered) it is likely that these models do not...
Inventors: Hadden; John W. (Cold Spring Harbor, NY)
Assignee: IRx Therapeutics, Inc. (New York, NY)
Date of First Priority Issue: Friday October 27th, 2000